

**Entitlement Offer cleansing notice under section 708AA(2)(f) Corporations Act –
 Factor Therapeutics Limited ACN 101 955 088 (ASX Code: FTT)**

Factor Therapeutics Limited (**Factor**) announced on 14 March 2018 that it will undertake a 1 for 7 pro rata non-renounceable entitlement offer of fully paid ordinary shares in Factor at an issue price of \$0.04 per new share (**New Shares**) to raise approximately \$4.17 million (**Entitlement Offer**).

The Entitlement Offer is fully underwritten by Taylor Collison Limited (**Underwriter**).

Factor will offer the New Shares for issue without disclosure to investors under section 708AA(2)(f) *Corporations Act 2001* (Cth) (**Corporations Act**) as notionally modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 (**Instrument 2016/84**).

Further details of the Entitlement Offer are set out in the Information Booklet that has been lodged with ASX today and that will be dispatched to eligible shareholders on or about 22 March 2018.

Details of the securities issued

Class of securities:	Ordinary shares
ASX Code of the securities:	FTT
Date of the issue or expected issue of the securities:	Tuesday, 17 April 2018
Total number of securities expected to be issued (subject to rounding of fractional entitlements):	104,291,826 New Shares

For the purposes of section 708AA(7) Corporations Act, Factor advises:

- 1 the New Shares will be issued without disclosure under part 6D.2 Corporations Act as notionally modified by Instrument 2016/84;
- 2 this notice is given under section 708AA(2)(f) Corporations Act as notionally modified by Instrument 2016/84;
- 3 as at the date of this notice, Factor has complied with:
 - (a) the provisions of chapter 2M Corporations Act as they apply to Factor; and
 - (b) section 674 Corporations Act;
- 4 as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) Corporations Act as notionally modified by Instrument 2016/84;

- 5 the issue of New Shares under the Entitlement Offer is not expected to have any material effect or consequence on the control of Factor, but is dependent on a number of factors including investor demand; and
- 6 given the structure of the Entitlement Offer as a pro rata offer, the potential effect that the issue of the New Shares will have on the control of Factor is as follows:
 - (a) if all eligible shareholders take up their Entitlement for New Shares under the Entitlement Offer, the Entitlement Offer will have no effect on the control of Factor;
 - (b) to the extent that any eligible shareholder fails to take up their Entitlement for New Shares under the Entitlement Offer, that eligible shareholder's percentage holdings in Factor will be diluted by those other eligible shareholders who take up some, all or more than their Entitlement; and
 - (c) although the issue of New Shares which are not taken up by eligible shareholders under the Entitlement Offer may increase the voting power of the Underwriter (or any sub-underwriters), it is not expected to have any material effect on the control of Factor.

Signed for and on behalf of Factor:



Melanie Farris
Company Secretary
Factor Therapeutics Limited

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead molecule (VF001) in Phase 2 for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit www.factor-therapeutics.com.